Company intelligence / Profile preview

Tianjin Bioroc Pharmaceutical & Biotech

Tianjin, Tianjin, China

Ownership: Private
Development stage: Other

Overview

Bioroc Pharmaceutical is a clinical-stage biotechnology company based in Tianjin, China, specializing in the discovery and development of innovative small molecule targeted therapies for oncology. The company leverages a proprietary structure-based drug design (SBDD) platform to develop high-potency, high-selectivity inhibitors against validated and emerging cancer targets. Its lead candidate, BRP-101, is a pan-FGFR inhibitor currently being evaluated in clinical trials for various solid tumors, including cholangiocarcinoma and urothelial cancer. Bioroc aims to address unmet medical needs in precision medicine through its robust internal R&D capabilities and strategic collaborations.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Tianjin Bioroc Pharmaceutical & Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tianjin Bioroc Pharmaceutical & Biotech.

Explore the full profile